We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 26 for:    Vercise
Previous Study | Return to List | Next Study

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02071134
Recruitment Status : Recruiting
First Posted : February 25, 2014
Last Update Posted : May 19, 2023
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.

Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for the programming of patients with the Boston Scientific's Vercise DBS Systems is also evaluated.


Condition or disease Intervention/treatment
Parkinson's Disease Device: Deep Brain Stimulation (DBS)

Detailed Description:

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.

Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline. Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for programming of patients is also evaluated.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Actual Study Start Date : March 4, 2014
Estimated Primary Completion Date : December 2028
Estimated Study Completion Date : December 2028

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Parkinson's disease
Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
 Device: Deep Brain Stimulation (DBS)
Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Other Names:
  • Vercise DBS System
  • Boston Scientific


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Improvement in patient's quality of life (QoL) during the study as compared with baseline [ Time Frame: up to 3 years ]
    Change in quality of life assessments during the study as compared with baseline


Other Outcome Measures:
  1. Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline [ Time Frame: up to 3 years ]
    Change in patient's motor symptoms as determined by UPDRS during the study as compared with baseline

  2. Change in medication usage during the study as compared with baseline [ Time Frame: up to 3 years ]
  3. Impression of change scores during the study as compared with baseline [ Time Frame: 3 years ]
    Impression of change scores during the study as compared with baseline


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with symptoms of Parkinson's disease that are not adequately controlled with medication
Criteria

Key Inclusion Criteria:

  • Meets criteria established in locally applicable Vercise System Direction for Use
  • At least 18 years old

Key Exclusion Criteria:

  • Meets any contraindication in the Vercise System locally applicable Directions for Use

Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02071134


Contacts
Layout table for location contacts
Contact: Heleen Scholtes 855-213-9890 BSNClinicalTrials@bsci.com
Contact: Alison Lewis 855-213-9890 BSNClinicalTrials@bsci.com

Locations
Show Show 77 study locations
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Study Director: Natalie Bloom Lyons Boston Scientific Neuromodulation Corporation
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT02071134    
Other Study ID Numbers: A4010
A4069 ( Other Identifier: Boston Scientific Corporation U.S. Study )
First Posted: February 25, 2014    Key Record Dates
Last Update Posted: May 19, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Boston Scientific Corporation:
Deep brain stimulation
Parkinson's disease
Vercise
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases